JAMA study finds Harvoni cost-effective

A Harvoni sofosbuvir/ledipasvir from Gilead Sciences Inc. (NASDAQ:GILD) was cost-effective across all ranges of disease severity.

The study assessed the benefits and costs of Harvoni on a simulated population of 1,000 60-year-old HCV patients. Researchers found that treatment with Harvoni at earlier stages of liver fibrosis resulted in a gain in quality-adjusted life years (QALYs), including increases of 2.27 QALYs for fibrosis scores of F3 vs. F4; 0.55 QALYs for F2 vs. F3; and 0.14 QALYs for F1 vs. F2. ...